Development of Broad Coronavirus Immunity Targeting the Fusion Peptide

项目摘要 这一修订后的申请最初是为了响应紧急奖的快速调查严重 急性呼吸道综合征冠状病毒2（SARS-CoV-2）和2019冠状病毒病（COVID-19） 通过PAR-20-177提交。然而，根据NIH的建议，我们将修改后的申请提交给 父PA-20-195，到期日为2020年11月16日。该申请的标题是“发展广泛的 靶向融合肽的冠状病毒免疫“。这支团队高度融合了 互补的专业知识，以开发一种独特的冠状病毒疫苗方法，提供更有效， 集中和扩大体液免疫。该建议集中在融合肽位点的 脆弱性，因为它已经研究不足，它是高度保守的，最近被确定为一个 人恢复期血清中中和抗体的表位。本项目的目标是：（1）发展泛 冠状病毒融合肽纳米颗粒和三聚体免疫原（2）开发免疫方案， 使用核酸递送的广泛中和抗体。

Project Summary This revised application was originally responding to the Emergency Award ‘Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)’ submitted through PAR-20-177. However, we are submitting the revised application, upon advice from NIH, to the parent PA-20-195 with a due date of Nov 16th 2020. The application is titled ‘Development of Broad Coronavirus Immunity Targeting the Fusion Peptide’. The assembled team brings together highly complementary expertise in order to develop a unique coronavirus vaccine approach to provide more effective, focused and broadened humoral immunity. This proposal focuses on the fusion peptide site of vulnerability as it has been understudied, it is highly conserved and recently been identified as an epitope of neutralizing antibodies in human convalescent sera. The project aims are: (1) Develop pan- coronavirus fusion peptide nanoparticle and trimer immunogens (2) Develop immunization regimes to induce broadly neutralizing antibodies using nucleic acid delivery.